Trimetrexate toxicity

Trimetrexate toxicity is an adverse clinical state resulting from exposure to the nonclassical dihydrofolate reductase inhibitor trimetrexate, serving as a key indication for protective or rescue therapy with reduced folates such as leucovorin Pathophysiologically, the absence of adequate reduced folate co-administration permits intracellular trimetrexate to deplete tetrahydrofolate pools in mammalian cells, halting thymidylate and purine synthesis and precipitating cellular arrest and apoptosis

Trimetrexate toxicity is an adverse clinical state resulting from exposure to the nonclassical dihydrofolate reductase inhibitor trimetrexate, serving as a key indication for protective or rescue therapy with reduced folates such as leucovorin

It predominantly affects rapidly dividing host tissues across the hematologic and gastrointestinal systems, presenting most commonly as dose-dependent myelosuppression—including severe neutropenia, thrombocytopenia, and anemia—alongside mucosal ulceration, elevated transaminases, and fever

It predominantly affects rapidly dividing host tissues across the hematologic and gastrointestinal systems, presenting most commonly as dose-dependent myelosuppression—including severe neutropenia, thrombocytopenia, and anemia—alongside mucosal ulceration, elevated transaminases, and fever